---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-004458"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:23:07.026303+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Arbutus appoints Melissa V. Rewolinski, PhD to its board of directors

## Summary
- Melissa V. Rewolinski appointed to board effective July 12, 2023; board expands to seven members.
- She joins Compensation Committee; receives $40,000 annual retainer plus $7,500 for committee service.
- Granted option for 110,000 common shares vesting over 3 years; exercise price based on July 12 closing price.
- Dr. Rewolinski brings 20+ years pharma experience; previously at Intercept, Amira, Pfizer; currently MVR Consulting.

## SEC filing metadata
- accession: 0001171843-23-004458
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/0001171843-23-004458-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/f8k_071223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-004458
- JSON: https://secwatch.observer/filing/0001171843-23-004458.json
- Plain text: https://secwatch.observer/filing/0001171843-23-004458.txt

## Key facts
- Executive change
  Melissa V. Rewolinski was appointed as Director at Arbutus Biopharma Corp.
  - Action: appointed
  - Role: Director
  source text: appointed Melissa V. Rewolinski, PhD to the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184323004458/0001171843-23-004458-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.